2.23 Covalent Inhibition of Btk with Clinical Development Compound AVL-292 Disrupts Signaling That Maintains the Microenvironment Necessary for Chronic Lymphocytic Leukemia Growth
Titel:
2.23 Covalent Inhibition of Btk with Clinical Development Compound AVL-292 Disrupts Signaling That Maintains the Microenvironment Necessary for Chronic Lymphocytic Leukemia Growth
Auteur:
Evans, E. Ponader, S. Karp, R. Tester, R. Sheets, M. Aslanian, S. St. Martin, T. Nacht, M. Zhu, Z. Chaturvedi, P. Witowski, S. Lounsbury, H. Stiede, K. Burger, J. Petter, R. Singh, J. Westlin, W.F.